Overall, the present review aims to explore the role of CRAF in cancer and highlights recent advances in RAF inhibitor combination therapies to improve treatment efficacy and mitigate toxicities in patients with RAF/RAS-mutant tumors. Here, RAF1 is linked to cancer.